
Sign up to save your podcasts
Or


Dr. SriniVas Sadda discusses development of macular atrophy in an analysis of HARBOR Study which investigated treatment of wet AMD using 0.5 mg and 2.0 mg of Ranibizumab dosing.
Full reference of the discussed article:
Sadda, S. R., Tuomi, L. L., Ding, B., Fung, A. E., & Hopkins, J. J. (2018). Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Ophthalmology. doi:10.1016/j.ophtha.2017.12.026
By Keyvan Koushan, MD, FRCSC4.4
1111 ratings
Dr. SriniVas Sadda discusses development of macular atrophy in an analysis of HARBOR Study which investigated treatment of wet AMD using 0.5 mg and 2.0 mg of Ranibizumab dosing.
Full reference of the discussed article:
Sadda, S. R., Tuomi, L. L., Ding, B., Fung, A. E., & Hopkins, J. J. (2018). Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Ophthalmology. doi:10.1016/j.ophtha.2017.12.026

43 Listeners

18 Listeners

97 Listeners

5 Listeners

4 Listeners

8 Listeners

22 Listeners

52 Listeners

10 Listeners

16 Listeners

18 Listeners

0 Listeners

1 Listeners

19 Listeners

0 Listeners